Daily16h
Bristol Myers Squibb application for Opdivo Plus Yervoy for MSI-H/ dMMR colorectal cancer accepted by USFDA
Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics ...
stocknews13m
3 Healthcare Stocks Tackling America’s Biggest Medical Challenges
From breakthrough treatments to AI-driven diagnostics, healthcare is evolving faster than ever. With increasing healthcare ...
Bristol-Myers Squibb Sees Unusually High Options Volume (NYSE:BMY)
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) saw some unusual options trading on Tuesday. Traders acquired 46,473 call options on the company. This represents an increase of approximately 61% ...
pharmaphorum23h
End of the line for BMS, Nektar's bempegaldesleukin/Opdivo alliance
Four years after Bristol-Myers Squibb paid $1.85 billion upfront to make Nektar's bempegaldesleukin a companion drug to its cancer immunotherapy Opdivo, the alliance is being discontinued.
appliedclinicaltrialsonline6h
PRESTIGE-AF Trial Shows DOACs Reduce Ischemic Stroke Risk in Intracerebral Hemorrhage Survivors, Heighten Bleeding Complications
Phase III PRESTIGE-AF trial shows that direct oral anticoagulants significantly lower the risk of ischemic stroke in ...
BioPharma Dive6h
Vertex ends gene editing research pact with Verve
Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.” ...